Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Status unconfirmed · Phase 2

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

Key facts

Study ID

NCT00005025

Run by

John Stoddard Cancer Center at Iowa Methodist Medical Center

Starts

2000-06-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Human Gene Therapy Research Institute — Des Moines, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.